Your browser doesn't support javascript.
Perspectives of Patients With Rheumatic Diseases in the Early Phase of COVID-19.
Antony, Anna; Connelly, Kathryn; De Silva, Thilinie; Eades, Laura; Tillett, William; Ayoub, Sally; Morand, Eric.
  • Antony A; School of Clinical Sciences, Monash University, and Monash Health, Victoria, Australia.
  • Connelly K; School of Clinical Sciences, Monash University, and Monash Health, Victoria, Australia.
  • De Silva T; Monash Health, Victoria, Australia.
  • Eades L; Monash Health, Victoria, Australia.
  • Tillett W; Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, and University of Bath, Bath, UK.
  • Ayoub S; School of Clinical Sciences, Monash University, and Monash Health, Victoria, Australia.
  • Morand E; School of Clinical Sciences, Monash University, and Monash Health, Victoria, Australia.
Arthritis Care Res (Hoboken) ; 72(9): 1189-1195, 2020 09.
Artículo en Inglés | MEDLINE | ID: covidwho-593679
ABSTRACT

OBJECTIVE:

To determine health perceptions of patients with rheumatic diseases in the early phase of the coronavirus disease 2019 (COVID-19) pandemic.

METHODS:

Rheumatology patients at a single center received via text message the Australian Rheumatology Association COVID-19 information sheet and an invitation to participate in a deidentified survey. Patient concerns regarding risks conferred by their rheumatologic disease or medications, impact of receiving the information sheet on the likelihood of staying on medication, and acceptance of telehealth were ascertained.

RESULTS:

A total of 2,630 patients received the text message, and the survey response rate was 21% (n = 550). The mean ± SD age of the participants was 52 ± 15.2 years, and 75.3% were female. Participants' highest ranked concern was that their medications would increase the severity of their COVID-19 symptoms (76.1%). The highest levels of concern were seen in patients taking combination conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and/or a biologic/targeted synthetic DMARD. There was no association between prednisolone dose and concern. While 63% of patients planned to continue their antirheumatic medications, a further 30% were more likely to continue taking their medications because of receiving the information. Telehealth was acceptable to 98.4% of patients, but 28.1% felt this was only appropriate while infection control measures were in place.

CONCLUSION:

Concerns regarding the risk of COVID-19 among patients taking antirheumatic drugs are common. Proactive dissemination of information is needed to address misconceptions related to medication risk, improve medication adherence, and minimize the risk of flares. Telehealth is acceptable to most patients during the COVID-19 pandemic.
Asunto(s)

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Aceptación de la Atención de Salud / Enfermedades Reumáticas / Infecciones por Coronavirus / Antirreumáticos / Betacoronavirus Tipo de estudio: Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Covid persistente Límite: Femenino / Humanos / Masculino / Middle aged Idioma: Inglés Revista: Arthritis Care Res (Hoboken) Asunto de la revista: Reumatología Año: 2020 Tipo del documento: Artículo País de afiliación: Acr.24347

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Aceptación de la Atención de Salud / Enfermedades Reumáticas / Infecciones por Coronavirus / Antirreumáticos / Betacoronavirus Tipo de estudio: Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Covid persistente Límite: Femenino / Humanos / Masculino / Middle aged Idioma: Inglés Revista: Arthritis Care Res (Hoboken) Asunto de la revista: Reumatología Año: 2020 Tipo del documento: Artículo País de afiliación: Acr.24347